Cargando…

611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers

BACKGROUND: Rates of hospitalization for bacterial infections due to opioid use disorder (OUD) are rising. Medication for OUD (MOUD) is an evidence-based intervention to treat OUD; however, MOUD initiation during hospitalization remain suboptimal. We aim to understand the continuum of MOUD and impac...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosenthal, Elana S, Catalanotti, Jillian S, Brokus, Christopher J, Carpenter, Joseph, Eaton, Ellen, Kuo, Irene, Steck, Alaina, Akselrod, Hana, Burgan, Kaylee W, Burkholder, Greer A, McGonigle, Keanan, Mai, William, Notis, Melissa, Sun, Junfeng, Kattakuzhy, Sarah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644045/
http://dx.doi.org/10.1093/ofid/ofab466.809
_version_ 1784609995280613376
author Rosenthal, Elana S
Catalanotti, Jillian S
Brokus, Christopher J
Carpenter, Joseph
Eaton, Ellen
Eaton, Ellen
Kuo, Irene
Steck, Alaina
Akselrod, Hana
Burgan, Kaylee W
Burkholder, Greer A
McGonigle, Keanan
Mai, William
Notis, Melissa
Sun, Junfeng
Kattakuzhy, Sarah
author_facet Rosenthal, Elana S
Catalanotti, Jillian S
Brokus, Christopher J
Carpenter, Joseph
Eaton, Ellen
Eaton, Ellen
Kuo, Irene
Steck, Alaina
Akselrod, Hana
Burgan, Kaylee W
Burkholder, Greer A
McGonigle, Keanan
Mai, William
Notis, Melissa
Sun, Junfeng
Kattakuzhy, Sarah
author_sort Rosenthal, Elana S
collection PubMed
description BACKGROUND: Rates of hospitalization for bacterial infections due to opioid use disorder (OUD) are rising. Medication for OUD (MOUD) is an evidence-based intervention to treat OUD; however, MOUD initiation during hospitalization remain suboptimal. We aim to understand the continuum of MOUD and impact of MOUD initiation on outcomes of patients hospitalized with infectious complications of OUD. METHODS: CHOICE is a retrospective review of adults hospitalized with an infectious complication of OUD and IDU at four academic medical centers (Figure 1). Patients were hospitalized between 1/1/2018 and 12/31/2018, had ICD9/10 diagnosis codes consistent with OUD and acute bacterial/fungal infection, and chart review verification of active infection associated with OUD. Data were abstracted regarding demographics, inpatient interventions, transitions of care, and 1 year outcomes. Linear regression model with generalized estimating equation was used to evaluate associations of MOUD initiation with outcomes. [Image: see text] RESULTS: 287 patients were predominately male (59%), white (63%), and median age 40 (32;52), with 72 (25%) uninsured, 103 (36%) unstably housed, and 84 (29%) were on MOUD prior to admission. 129 (45%) received MOUD during admission, 113 (39%) had MOUD prescribed on discharge, and 24 (8.4%) were linked to MOUD after admission [fig 2]. During sentinel admission, 62 (22%) were discharged prematurely/eloped, of whom 43 (69%) left without an antibiotic plan. Of the 202 (71%) not on MOUD at baseline, 55 (27%) initiated MOUD during admission. MOUD initiation was associated with higher odds of planned discharge (OR 6.7; p=0.0002) and being discharged on MOUD (OR 174; p< 0.0001) [fig 3]. Being uninsured was associated with lower odds of planned discharge (OR 0.55; < 0.0001) and discharge on MOUD (OR 0.59; p=0.02). CHOICE Baseline Demographics (N=287) [Image: see text] [Image: see text] [Image: see text] CONCLUSION: Across four healthcare systems, we found that patients hospitalized with infectious complications of OUD had low rates of MOUD initiation and high rates of premature discharge with incomplete ID treatment. Interventions to increase MOUD initiation and expand access to insurance may serve to mitigate the morbidity and mortality associated with OUD-related infections. DISCLOSURES: Elana S. Rosenthal, MD, Gilead Sciences (Research Grant or Support)Merck (Research Grant or Support) Ellen Eaton, MD , Gilead (Grant/Research Support) Ellen Eaton, MD , Gilead (Individual(s) Involved: Self): Research Grant or Support Greer A. Burkholder, MD, MSPH, Eli Lilly (Grant/Research Support) Sarah Kattakuzhy, MD, Gilead Sciences (Scientific Research Study Investigator, Research Grant or Support)
format Online
Article
Text
id pubmed-8644045
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86440452021-12-06 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers Rosenthal, Elana S Catalanotti, Jillian S Brokus, Christopher J Carpenter, Joseph Eaton, Ellen Eaton, Ellen Kuo, Irene Steck, Alaina Akselrod, Hana Burgan, Kaylee W Burkholder, Greer A McGonigle, Keanan Mai, William Notis, Melissa Sun, Junfeng Kattakuzhy, Sarah Open Forum Infect Dis Poster Abstracts BACKGROUND: Rates of hospitalization for bacterial infections due to opioid use disorder (OUD) are rising. Medication for OUD (MOUD) is an evidence-based intervention to treat OUD; however, MOUD initiation during hospitalization remain suboptimal. We aim to understand the continuum of MOUD and impact of MOUD initiation on outcomes of patients hospitalized with infectious complications of OUD. METHODS: CHOICE is a retrospective review of adults hospitalized with an infectious complication of OUD and IDU at four academic medical centers (Figure 1). Patients were hospitalized between 1/1/2018 and 12/31/2018, had ICD9/10 diagnosis codes consistent with OUD and acute bacterial/fungal infection, and chart review verification of active infection associated with OUD. Data were abstracted regarding demographics, inpatient interventions, transitions of care, and 1 year outcomes. Linear regression model with generalized estimating equation was used to evaluate associations of MOUD initiation with outcomes. [Image: see text] RESULTS: 287 patients were predominately male (59%), white (63%), and median age 40 (32;52), with 72 (25%) uninsured, 103 (36%) unstably housed, and 84 (29%) were on MOUD prior to admission. 129 (45%) received MOUD during admission, 113 (39%) had MOUD prescribed on discharge, and 24 (8.4%) were linked to MOUD after admission [fig 2]. During sentinel admission, 62 (22%) were discharged prematurely/eloped, of whom 43 (69%) left without an antibiotic plan. Of the 202 (71%) not on MOUD at baseline, 55 (27%) initiated MOUD during admission. MOUD initiation was associated with higher odds of planned discharge (OR 6.7; p=0.0002) and being discharged on MOUD (OR 174; p< 0.0001) [fig 3]. Being uninsured was associated with lower odds of planned discharge (OR 0.55; < 0.0001) and discharge on MOUD (OR 0.59; p=0.02). CHOICE Baseline Demographics (N=287) [Image: see text] [Image: see text] [Image: see text] CONCLUSION: Across four healthcare systems, we found that patients hospitalized with infectious complications of OUD had low rates of MOUD initiation and high rates of premature discharge with incomplete ID treatment. Interventions to increase MOUD initiation and expand access to insurance may serve to mitigate the morbidity and mortality associated with OUD-related infections. DISCLOSURES: Elana S. Rosenthal, MD, Gilead Sciences (Research Grant or Support)Merck (Research Grant or Support) Ellen Eaton, MD , Gilead (Grant/Research Support) Ellen Eaton, MD , Gilead (Individual(s) Involved: Self): Research Grant or Support Greer A. Burkholder, MD, MSPH, Eli Lilly (Grant/Research Support) Sarah Kattakuzhy, MD, Gilead Sciences (Scientific Research Study Investigator, Research Grant or Support) Oxford University Press 2021-12-04 /pmc/articles/PMC8644045/ http://dx.doi.org/10.1093/ofid/ofab466.809 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Rosenthal, Elana S
Catalanotti, Jillian S
Brokus, Christopher J
Carpenter, Joseph
Eaton, Ellen
Eaton, Ellen
Kuo, Irene
Steck, Alaina
Akselrod, Hana
Burgan, Kaylee W
Burkholder, Greer A
McGonigle, Keanan
Mai, William
Notis, Melissa
Sun, Junfeng
Kattakuzhy, Sarah
611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title_full 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title_fullStr 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title_full_unstemmed 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title_short 611. No Source Control: Low Rates of Medication for Opioid Use Disorder in Individuals Hospitalized with Infectious Complications of Injection Opioid Use at Four Academic Medical Centers
title_sort 611. no source control: low rates of medication for opioid use disorder in individuals hospitalized with infectious complications of injection opioid use at four academic medical centers
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644045/
http://dx.doi.org/10.1093/ofid/ofab466.809
work_keys_str_mv AT rosenthalelanas 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT catalanottijillians 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT brokuschristopherj 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT carpenterjoseph 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT eatonellen 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT eatonellen 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT kuoirene 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT steckalaina 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT akselrodhana 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT burgankayleew 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT burkholdergreera 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT mcgoniglekeanan 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT maiwilliam 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT notismelissa 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT sunjunfeng 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters
AT kattakuzhysarah 611nosourcecontrollowratesofmedicationforopioidusedisorderinindividualshospitalizedwithinfectiouscomplicationsofinjectionopioiduseatfouracademicmedicalcenters